secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001140361-24-035212
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics promotes Khurram Jamil to CMO, replacing Pol Boudes
-------------------------------------------------------------------------

- Dr. Jamil appointed Chief Medical Officer effective August 1, 2024, succeeding Dr. Pol Boudes.
- Annual base salary of $500,000, 30% target bonus, 10,000 restricted shares, options for 100,000 shares.
- Jamil joined Galectin in March 2024 as VP Clinical Development; previously at Mallinckrodt Pharmaceuticals.
- Company reaffirms interim analysis of NAVIGATE Phase 2b/3 trial for belapectin in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/0001140361-24-035212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/ef20033332_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-035212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer